Nordicus Partners Corporation's Ambition for Nasdaq Listing
BEVERLY HILLS — Nordicus Partners Corporation (OTCQB: NORD) is taking a significant step by applying for a listing on the Nasdaq Capital Market. This move aims to elevate the company's visibility and enhance its position within the life sciences sector.
CEO Statement on the Uplisting Decision
Henrik Rouf, the Chief Executive Officer of Nordicus, expressed his enthusiasm about this strategic decision. "We are elated to announce our application to uplist our shares on Nasdaq," he stated. This decision follows the successful completion of two acquisitions that were finalized last year. Furthermore, Nordicus is making substantial progress in developing its proprietary drug pipeline, which focuses on conditions such as periodontitis and oral leukoplakia.
The Benefits of a Nasdaq Listing
Raising the company’s profile through a Nasdaq listing will provide multiple advantages. Not only does it help in enhancing liquidity, but it also serves as a magnet for institutional investors. The ability to access capital at more favorable terms is a game-changer that can accelerate the company’s growth trajectory. Rouf highlighted that this is a pivotal moment for Nordicus as it transitions to a globally recognized exchange.
Understanding the Approval Process
While Nordicus is optimistic about meeting all the necessary listing criteria set forth by Nasdaq, it is important to acknowledge that the approval process is not guaranteed. The company will remain on the OTCQB Market under the ticker NORD until the uplisting is completed and approved.
The Strategic Importance of the Listing
This uplisting is a crucial aspect of Nordicus's long-term strategy. As the only publicly traded business accelerator focusing on Nordic life sciences companies in the U.S., Nordicus understands the importance of having a solid foundation in capital markets.
Company Background: Who is Nordicus Partners Corporation?
Nordicus Partners Corporation specializes in supporting Nordic and U.S. life sciences companies in market entry strategies. With an impressive track record in corporate finance, Nordicus has established itself as a leading force in business development and growth strategies. The company holds 100% of Orocidin A/S, a Danish biotech firm dedicated to developing innovative therapies for periodontitis, and Bio-Convert A/S, which is transforming the treatment landscape for oral leukoplakia.
Commitment to Innovation and Growth
With a robust pipeline of drug development initiatives and a commitment to innovation, Nordicus is poised for success. The advancements in their research and development efforts underline their commitment to improving health outcomes, especially in challenging medical conditions.
Contact Information
For those seeking additional information, please feel free to reach out to:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Frequently Asked Questions
What is Nordicus Partners Corporation?
Nordicus Partners Corporation is a financial consulting firm focused on helping Nordic and U.S. life sciences companies enter the U.S. market.
What does uplisting to Nasdaq mean for Nordicus?
Uplisting to Nasdaq would enhance Nordicus's visibility and liquidity while attracting more institutional investors.
What advantages will a Nasdaq listing provide?
A Nasdaq listing will facilitate greater access to capital, improve visibility, and strengthen market confidence.
Who is Henrik Rouf?
Henrik Rouf is the Chief Executive Officer of Nordicus Partners Corporation, overseeing the company's strategic direction.
How can I reach Nordicus for inquiries?
You can reach out via email at hr@nordicuspartners.com or call +1 310 666 0750.
